Sector News

Amgen trims 172 more jobs, this time in operations, R&D and sales

November 20, 2019
Life sciences

Amgen’s top line has suffered from knockoff competition in recent quarters, and now the pain is moving to its payroll. After disclosing almost 150 cuts on the East Coast last week, the biotech giant now says it’s cutting 172 staffers at its headquarters and in the field.

The layoffs will hit R&D, operations and commercial employees, Amgen said in a California WARN filing (PDF). The majority of the jobs targeted are field-based jobs throughout the U.S., though some cuts will hit its headquarters in Thousand Oaks, California.

The layoffs will take effect Dec. 31, the filing said.

An Amgen spokeswoman said the company, like others, “regularly evaluates and adjusts staffing levels to meet the needs of the business.”

“While these decisions are never easy, we believe our ability to compete will be strengthened by a tighter focus on investments that can help bring important medicines to patients to treat serious, life-threatening illnesses,” she added.

The cuts come as Amgen deals with patent expirations and new biosimilar rivals. The company faces generic versions of its thyroid drug Sensipar and recently launched copycats to its white blood cell boosters Neupogen and Neulasta—plus anemia drug Epogen. Biosimilar versions of its immunology med Enbrel are approved but not yet launched. Amgen defeated a patent challenge on Enbrel from Sandoz over the summer.

Thanks to new rivals, the drugmaker’s sales dipped 2% in the second quarter and 3% in the third quarter versus the same periods last year.

Meanwhile, as biosims take a toll on its drugs, the company is hitting back with its own biosimilars to other companies’ blockbusters—and those meds brought in $173 million last quarter.

Last week, Amgen said it’d cut 149 jobs in Massachusetts by the end of the year as it exits neuroscience R&D.

Amgen in 2014 laid off 2,900 employees in a major restructuring, and the company in 2017 cut jobs as part of a plan to shift employment to a new facility in Tampa.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.